Twitter | Pretraživanje | |
Spring Bank
Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharma company developing a novel class of therapeutics using our SMNH chemistry platform.
431
Tweetovi
1.142
Pratim
1.324
Osobe koje vas prate
Tweetovi
Spring Bank 19. pro
Designed to resemble naturally occurring nucleotides and nucleic acids in the body, our SMNH compounds cause no observed non-specific immune response and target a broad range of disease, including viral diseases and cancers. :
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 18. pro
Developed for the treatment of , inarigivir is an orally-available selective immunomodulator that stimulates the innate immune response and inhibits viral replication. Watch this video to learn more :
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 17. pro
Citing our two clinical programs, multiple data readouts, high quality partners and a cash runway beyond 2021, notes that Spring Bank could be undervalued. Read more. : FLS Disclaimer:
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 16. pro
Inarigivir selectively activates within cells infected with , inhibiting viral replication and causing the induction of intracellular interferon signaling pathways for antiviral defense. Learn more about this mechanism here :
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 13. pro
Among our pipeline of compounds, we plan to focus most on the inarigivir compound for treatment and SB 11285 for applications. See our full pipeline here. :
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 12. pro
We design our proprietary SMNH compounds to bind specifically to their intended proteins, producing high therapeutic benefit over current therapies. We are committed to the highest standards of scientific excellence and integrity :
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 11. pro
STimulator of INterferon Genes, or STING, is a protein that can activate the body’s innate immune system. SB 11285 is an agent that activates the STING pathway currently being developed for the treatment of some cancers. :
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 10. pro
We released results from the first cohort of the clinical trial examining the co-administration of the low dose of inarigivir 50mg and the nucleoside analog, Vemlidy®. . Learn more about this trial here from :
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 9. pro
Novel Small Molecule Drug Discovery Platform Harnesses Immune System to Defeat Cancers, Viral Infections & Inflammatory Diseases. Read the article from Dr. Kris Iyer in Drug Development & Delivery (FLS Disclaimer: ):
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 27. stu
Designed to resemble naturally occurring nucleotides and nucleic acids in the body, our SMNH compounds are relatively easy to manufacture and include no observed non-specific immune response :
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 26. stu
Inarigivir, our most advanced product candidate, has the potential to provide a functional cure for . Watch this video to learn more about inarigivir’s novel mechanism of action :
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 25. stu
We are a clinical-stage company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid platform. Want more investment-relevant info? Check here :
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 22. stu
Learn all about our development pipelines in our three main therapeutic areas: , , and inflammatory diseases :
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 21. stu
At Spring Bank, we are committed to the highest standards of scientific excellence and integrity for the benefit of patients and the medical community. Learn more about our mission :
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 20. stu
Our small molecule nucleic acid hybrid compounds act directly on target proteins, and have the potential to be used as part of combinatorial treatments, for example in with other antivirals :
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 18. stu
Since inception, we have sought to apply our small molecule nucleic acid hybrid chemistry platform toward the discovery and development of novel drugs. The work has culminated in inarigivir, which is now being studied in Phase 2 clinical trials :
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 15. stu
Want to dive deep into the science and documentation behind our technology? Take a look at our publications :
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 14. stu
STimulator of INterferon Genes, or STING, is a protein that has the power to activate the body’s innate immune system. SB 11285 is a potent immunotherapeutic agent that activates the STING pathway. Read more about it here. :
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 13. stu
We are focusing the development of our two most advanced product candidates, inarigivir and SB 11285, on the treatment of and various cancers respectively :
Reply Retweet Označi sa "sviđa mi se"
Spring Bank 12. stu
Did you know that attaining a functional cure for chronic will likely require modulation of the immune system? Our product candidate inarigivir is being developed with this in mind. Learn more about it :
Reply Retweet Označi sa "sviđa mi se"